Vamvakas S, Bahner U, Heidland A (1998) Cancer in end-stage renal disease: potential factors involved -editorial. Am J Nephrol 18:89–95

Article  CAS  PubMed  Google Scholar 

Maisonneuve P, Agodoa L, Gellert R et al (1999) Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354:93–99

Article  CAS  PubMed  Google Scholar 

Yossepowitch O, Sagy I, Margel D et al (2012) Urothelial carcinoma of the bladder in patients on hemodialysis: clinical characteristics and oncological outcomes. J Urol 187:1215–1219

Article  PubMed  Google Scholar 

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 83:1218–1230

Article  Google Scholar 

Hirsch JS, Wanchoo R, Ng JH et al (2020) Use of immune checkpoint inhibitors in end stage kidney disease patients, single center experience and review of the literature. Kidney360 1:399–402

Article  PubMed  PubMed Central  Google Scholar 

Kitchlu A, Jhaveri KD, Sprangers B et al (2021) Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J 14:2012–2022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  CAS  PubMed  Google Scholar 

Janus N, Launay-Vacher V, Thyss A et al (2013) Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24:501–507

Article  CAS  PubMed  Google Scholar 

von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

Article  PubMed  Google Scholar 

Meluch AA, Greco FA, Burris HA et al (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19:3018–3024

Article  CAS  PubMed  Google Scholar 

Ezaki T, Matsumoto K, Morita S et al (2016) A case of gemcitabine and cisplatin chemotherapy in a patient with metastatic urothelial carcinoma receiving hemodialysis. Clin Genitourin Cancer 14:e413-416

Article  PubMed  Google Scholar 

Hiraike M, Hiraki Y, Misumi N et al (2012) Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol 69:845–848

Article  CAS  PubMed  Google Scholar 

Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27:256–269

Article  CAS  PubMed  Google Scholar 

Kiani A, Köhne CH, Franz T et al (2003) Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 51:266–270

Article  PubMed  Google Scholar 

Cheun H, Kim M, Lee H et al (2019) Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs 37:579–583

Article  PubMed  Google Scholar 

Parisi A, Cortellini A, Cannita K et al (2019) Safe administration of anti-PD-L1 atezolizumab in a patient with metastatic urothelial cell carcinoma and end-stage renal disease on dialysis. Case Rep Oncol Med 10:3452762

Google Scholar 

Kuo MC, Su PJ, Huang CC et al (2020) Safety and efficacy of immune checkpoint inhibitors for patients with metastatic urothelial carcinoma and end-stage renal disease: experiences from real-world practice. Front Oncol 10:584834

Article  PubMed  PubMed Central  Google Scholar 

Jain J, Stein J, Garje R (2020) Evaluation of checkpoint inhibitors in cancer patients with end-stage renal disease on hemodialysis: case series and review of the literature. J Immunother 43:244–249

Article  PubMed  Google Scholar 

Vitorino M, Santos C (2022) Use of pembrolizumab in end-stage renal disease: a case report with complete response. Case Rep Oncol 15:187–190

Article  PubMed  PubMed Central  Google Scholar